| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/19/2009 | US20090074884 Family of pfkfb3 inhibitors with anti-neoplastic activities |
| 03/19/2009 | US20090074879 Wound-Healing Composition |
| 03/19/2009 | US20090074875 Nanoparticulate compositions having lysozyme as a surface stabilizer |
| 03/19/2009 | US20090074873 Nanoparticulate beclomethasone dipropionate compositions |
| 03/19/2009 | US20090074872 Active Agent Formulations, Methods of Making, and Methods of Use |
| 03/19/2009 | US20090074871 Composition for filling bone defects |
| 03/19/2009 | US20090074870 Alteration of cell membrane for new functions |
| 03/19/2009 | US20090074869 Pharmaceutical formulations |
| 03/19/2009 | US20090074868 Photoinitiated tissue filler |
| 03/19/2009 | US20090074863 Dosage Forms Containing A PPI, NSAID And A Buffer |
| 03/19/2009 | US20090074862 Low-dose doxepin formulations and methods of making and using the same |
| 03/19/2009 | US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 03/19/2009 | US20090074858 Sustained-release formulation |
| 03/19/2009 | US20090074857 Glycerophospholipids for the improvement of cognitive functions |
| 03/19/2009 | US20090074856 Crystalline pyrimidine nucleoside derivative suspensions in capsules |
| 03/19/2009 | US20090074854 Combined-step process for pharmaceutical compositions |
| 03/19/2009 | US20090074852 Lipoplex formulations for specific delivery to vascular endothelium |
| 03/19/2009 | US20090074851 Cpg-packaged liposomes |
| 03/19/2009 | US20090074848 Combination formulations of cytidine analogs and platinum agents |
| 03/19/2009 | US20090074847 Transport System In Biological Systems |
| 03/19/2009 | US20090074845 Transdermal active principle delivery means |
| 03/19/2009 | US20090074844 Trenadermal absorption preparation |
| 03/19/2009 | US20090074839 Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications |
| 03/19/2009 | US20090074833 Bridged polycyclic compound based compositions for controlling bone resorption |
| 03/19/2009 | US20090074831 LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS |
| 03/19/2009 | US20090074830 Anti-angiogenic compositions and methods of use |
| 03/19/2009 | US20090074828 Poly(amino acid) targeting moieties |
| 03/19/2009 | US20090074824 Stable nanocapsule systems for the administration of active molecules |
| 03/19/2009 | US20090074796 Pde5 inhibitor compositions and methods for immunotherapy |
| 03/19/2009 | US20090074795 Methods for addressing ocular diseases through interference with the wnt signaling pathway |
| 03/19/2009 | US20090074794 for use in the treatment of crohn's and ulcerative colitis; administering a composition comprising an effective amount of at least one isolated mammalian anti-tumor necrosis factor (TNF) antibody comprising at least one variable region comprising SEQ ID NO:7 and 8 |
| 03/19/2009 | US20090074792 Compositions containing full-length L1R nucleic acid and endoplasmic reticulum-targeting sequence, and methods of use |
| 03/19/2009 | US20090074791 Phenylisoquinoline and Phenylquinazoline Derivatives |
| 03/19/2009 | US20090074786 Formulations for treating ocular diseases and conditions |
| 03/19/2009 | US20090074785 Compositions and methods for treatment of colorectal cancer |
| 03/19/2009 | US20090074783 isolated and purified protein produced by a naturally occurring Babesia sp. and an isolated and purified nucleic acid encoding the above protein; use in diagnosing and treating a mammal infected with a Babesia sp. |
| 03/19/2009 | US20090074777 Wnt proteins and detection and treatment of cancer |
| 03/19/2009 | US20090074776 relates to nucleic acid sequences encoding a member of the fibroblast growth factor (FGF) family, and to polypeptides encoded by the nucleic acid sequence |
| 03/19/2009 | US20090074773 Cancer vaccine |
| 03/19/2009 | US20090074767 Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof |
| 03/19/2009 | US20090074761 Therapeutic beta-glucan combinations |
| 03/19/2009 | US20090074756 Use of llt1 and/or cd161 for modulatting the activity of cells of the immune system |
| 03/19/2009 | US20090074754 Methods and compositions useful in the treatment of mucositis |
| 03/19/2009 | US20090074753 Platelet-derived growth factor compositions and methods of use thereof |
| 03/19/2009 | US20090074746 Compounds to treat alzheimer's disease |
| 03/19/2009 | US20090074745 Treatment and prevention of tissue damage |
| 03/19/2009 | US20090074743 Inositol Pyrophosphates Determine Exocytotic Capacity |
| 03/19/2009 | US20090074740 Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT) |
| 03/19/2009 | US20090074738 1-substituted-3-beta-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same |
| 03/19/2009 | US20090074727 Method of treating solid tumor |
| 03/19/2009 | US20090074724 Materials and methods for inhibiting wip1 |
| 03/19/2009 | US20090074723 Method of Treating or Retarding the Development of Blindness |
| 03/19/2009 | US20090074722 Products and methods for treating PTP lar diseases |
| 03/19/2009 | US20090074721 Methods for treating viral infection with oral or injectibel drug solution |
| 03/19/2009 | US20090074717 Anti-viral compounds, compositions, and methods of use |
| 03/19/2009 | US20090074716 method for treating influenza virus infection |
| 03/19/2009 | US20090074715 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester |
| 03/19/2009 | US20090074710 Method of treatment using a cytokine able to bind il-18bp to inhibit the activity of a second cytokine |
| 03/19/2009 | US20090074708 Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B) |
| 03/19/2009 | US20090074707 Shaped body and method for production of said body |
| 03/19/2009 | US20090074691 Topical Delivery System for Antiaging and Skin Whitening Agents |
| 03/19/2009 | US20090074688 Antimicrobial Lotion Compositions |
| 03/19/2009 | US20090074682 Silane esters and amides of 2-oxothiazolidine-4-carboxylic acid, and cosmetic uses thereof |
| 03/19/2009 | US20090074677 Neuroactive steroid compositions and methods of use therefor |
| 03/19/2009 | US20090074676 Inhibition of p38 MAPK For Treatment Of Obesity |
| 03/19/2009 | US20090074675 Indazoles as glucocorticoid receptor ligands |
| 03/19/2009 | US20090074665 Diagnosis and treatment of cancer:I |
| 03/19/2009 | DE102008046530A1 Verfahren zur Herstellung von Escitalopram Process for the preparation of escitalopram |
| 03/19/2009 | DE102007045038A1 Arzneimittel zur Behandlung oder Prävention von Proteinurie Drugs for the treatment or prevention of proteinuria |
| 03/19/2009 | DE102007044296A1 New carbonyl containing chemical compounds are protein modulators useful e.g. for the polymerization of proteins with transglutaminase, in transglutaminase catalyzed process, and for the modification of proteins with transglutaminase |
| 03/19/2009 | DE102007044277A1 Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln Substituted nicotinamide compounds and their use in medicaments |
| 03/19/2009 | DE102007044202A1 Composition, useful for wound treatment, preferably poor or non-healing open wounds in humans, comprises hyaluronic acid, urea, and colloidal silver |
| 03/19/2009 | DE102007044093A1 Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben Nucleic acid-containing cosmetic and / or pharmaceutical preparations for the induction of antimicrobial peptides in epithelial tissues deck |
| 03/19/2009 | DE102007044032A1 New substituted heteroaryl compounds are hypoxia-inducible factor prolyl-4-hydroxylase inhibitors useful to treat and/or prevent e.g. circulatory heart diseases, heart failure, anemia, chronic kidney diseases and renal failure |
| 03/19/2009 | CA2704129A1 Preparation and component intended to be added to a tobacco product |
| 03/19/2009 | CA2702063A1 Mpzp: a small molecule corticotropin-releasing factor type 1 receptor (crf1) antagonist |
| 03/19/2009 | CA2699630A1 Transdermal, alcohol-free, pharmaceutical compositions |
| 03/19/2009 | CA2699521A1 Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, .alpha.-amylase and .alpha.-glucosidase activity in mammals |
| 03/19/2009 | CA2699472A1 Polymorph forms of (s)-2-((4-benzofuranyl)carbonylaminomethyl)-1-((4-(2-methyl-5-(4-fluorophenyl)thiazolyl)carbonyl)piperidine |
| 03/19/2009 | CA2699468A1 Composition for preventing virus infection comprising poly-gamma-glutamic acid |
| 03/19/2009 | CA2699464A1 Piperidine derivatives as nk3 receptor antagonists |
| 03/19/2009 | CA2699463A1 Novel compounds active as muscarinic receptor antagonists |
| 03/19/2009 | CA2699414A1 Treatment of vasomotor symptoms |
| 03/19/2009 | CA2699403A1 Pharmaceutical composition with anti-diabetic action |
| 03/19/2009 | CA2699384A1 Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| 03/19/2009 | CA2699383A1 Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists |
| 03/19/2009 | CA2699382A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 03/19/2009 | CA2699286A1 Piperidine derivatives as agonists of muscarinic receptors |
| 03/19/2009 | CA2699285A1 Process for the preparation of compounds useful as inhibitors of sglt |
| 03/19/2009 | CA2699213A1 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus |
| 03/19/2009 | CA2699210A1 Titration package for neramexane and its use in the treatment of an inner ear disorder |
| 03/19/2009 | CA2699209A1 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss |
| 03/19/2009 | CA2699207A1 Interval therapy for the treatment of tinnitus |
| 03/19/2009 | CA2699202A1 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| 03/19/2009 | CA2699157A1 Compounds that modulate intracellular calcium |
| 03/19/2009 | CA2699152A1 Spirocyclic aminoquinolones as gsk-3 inhibitors |
| 03/19/2009 | CA2699151A1 Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
| 03/19/2009 | CA2699142A1 Abuse resistant drug formulation |
| 03/19/2009 | CA2699040A1 Perharidines |
| 03/19/2009 | CA2699038A1 Phthalazinone derivatives |